Skip to main content
Lynch syndrome Online training for pathologists M3 IHC interpretation
Page
1
There was an error on your page. Please correct any required fields and submit again.
Go to the first error
*
1.
Question 1.
What is your name?
Required
- Required.
*
2.
Question 2.
The MMR proteins are best considered in 2 pairs due to the way the proteins dimerise. What are these 2 pairs? Please select 2 answers
Required
- Required.
MLH1 and PMS2
MLH1 and MSH2
MLH1 and MSH6
MSH2 and MSH6
PMS2 and MSH6
*
3.
Question 3.
How frequently is abnormal staining observed in colorectal and Endometrial cancers? Please, select 2 answers
Required
- Required.
10% Colorectal cancer cases
15% Colorectal cancer cases
25% Colorectal cancer cases
11% Endometrial cancer cases
21% Endometrial cancer cases
31% Endometrial cancer cases
*
4.
Question 4.
What is the null phenotype?
Required
- Required.
Complete loss of all 4 proteins
Clonal loss of MSH2
Clonal loss of MSH2 and MSH6
Clonal loss of PMS2
*
5.
Question 5.
When you face an unusual case, what are the reassuring features?
Required
- Required.
Additional clonal loss of MSH6 +/- MSH2 in sporadic MLH1/PMS2 loss (confirmed BRAF mutation or MLH1 promoter hypermethylation)
Synchronous tumours with different results
Advanced age (though can be misleading)
All of the above
*
6.
Question 6.
When you face an unusual case, what are the worrying features?
Required
- Required.
Complete loss of MSH6 +/- MSH2 in any context (confirm on resection if available)
Synchronous tumours with the same pattern of loss
All of the above
There are no worrying features